Moreover, the lack of biomarkers for aggressive disease, combined with opportunistic PSA screening, has led to large scale overdiagnosis and overtreatment of clinically insignificant prostate cancers, thus new biomarkers are urgently needed. This evidence concerns the gene KLK3 and prostate carcinoma.